Skip to main navigation Skip to search Skip to main content

PICCle: Phase I/II clinical trial to assess the efficacy and safety of the drug AZD2281, a PARP-inhibitor, in relapsed and refractory Chronic Lymphocytic Leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patien

Project Details

Short titlePICCle: Phase I/II clinical trial to assess the efficacy and safety of the drug AZD2281, a PARP-inhibitor, in relapsed and refractory Chronic Lymphocytic Leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patien
StatusFinished
Effective start/end date1/09/09 → 31/12/17

Funding

  • BLOODWISE
  • THE BRITISH SOCIETY FOR HAEMATOLOGY
  • AstraZeneca